No Data
Zhejiang Hisun Pharmaceutical Registers Cancer Drug in China
Zhejiang Hisun Pharmaceutical (600267.SH): Everolimus tablets have obtained the pharmaceutical registration certificate.
On January 9, GLG announced that Zhejiang Hisun Pharmaceutical (600267.SH) recently received the drug registration certificate for Everolimus tablets approved by the National Medical Products Administration. Everolimus is suitable for adult patients with advanced renal cell carcinoma who have previously failed treatment with Sunitinib or Sorafenib; adult patients with unresectable, locally advanced, or metastatic, well-differentiated (moderately differentiated or highly differentiated) progressive pancreatic neuroendocrine tumors; adult patients with unresectable, locally advanced, or metastatic, well-differentiated, progressive non-functional gastrointestinal or pulmonary neuroendocrine tumors (NET) who require treatment.
Zhejiang Hisun Pharmaceutical (600267.SH): plans to invest 50 million yuan in Jisheng Aoma's capital increase.
On December 27, Gelonghui reported that Zhejiang Hisun Pharmaceutical (600267.SH) announced that Nanjing Jisheng Aoma Biomedical Co., Ltd. (referred to as "Jisheng Aoma") was established in 2021, and its main product indications include allergic rhinitis, allergic dermatitis, respiratory infections, vaccine adjuvants, etc. To support its own Innovative Drugs development, Jisheng Aoma recently plans to raise no more than 0.1 billion yuan. Given that the disease areas of Jisheng Aoma's pipeline products align with the company's Global Strategy, to promote cooperation with Jisheng Aoma and advance the company’s own Innovative Drugs development, it is agreed that the company will participate in this round of capital increase with its self-raised funds amounting to 50 million yuan, if...
Is Zhejiang Hisun Pharmaceutical (SHSE:600267) Using Too Much Debt?
Zhejiang Hisun Pharmaceutical (600267.SH): Apremilast tablets and posaconazole enteric-coated tablets are expected to win centralized procurement bidding.
Zhejiang Hisun Pharmaceutical (600267.SH) announced that on December 12, 2024, the company participated in a joint procurement...
Zhejiang Hisun Pharmaceutical (600267.SH): Participation in the national pharmaceutical centralized procurement aims to win the bid.
Gelonghui reported on December 13 that Zhejiang Hisun Pharmaceutical (600267.SH) announced that on December 12, 2024, the company participated in the bidding for the 10th batch of national centralized pharmaceutical procurement organized by the Joint Procurement Office (hereinafter referred to as the "Joint Procurement Office"). After the opening and evaluation of bids by the Joint Procurement Office, the company's products, Aprepitant tablets and Posaconazole enteric-coated tablets, are proposed to win the bid for this centralized procurement. Aprepitant tablets and Posaconazole enteric-coated tablets have been selected for supply provinces based on the market potential of each province, and the results of the selection will be officially announced after being posted by the Joint Procurement Office.
Benign Growth For Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) Underpins Stock's 27% Plummet
